Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of
combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP
rintatolimod (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (IVP)
for patients with recurrent platinum-sensitive ovarian cancer (OC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Robert Edwards
Collaborators:
AIM ImmunoTech Inc. Hemispherx Biopharma Merck Sharp & Dohme Corp.